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Abstract
Objectives: This study was undertaken to determine: 1) Type and prevalence of founder mutations BRCA1
and BRCA2 genes in Polish families with strong aggregation of breast and/or ovarian cancer. 2) Risk of breast
and/or ovarian cancer depending on type of BRCA1 gene mutation. 3) Prevalence of BRCA1 mutation and
of other alleles presumably linked with predisposition to breast cancer in unselected Polish patients with breast
cancer. 4) Risk of breast cancer in patients with 5972C/T polymorphism that alters the BRCA2 protein structure.
Summary of the results: 1. Among 66 families from several regions in Poland with a strong aggregation of breast/ovarian
cancer, founder mutation of the BRCA1 gene were disclosed in 34 families and of the BRCA2 gene in on family.
Altogether, seven different mutations were disclosed. Five mutations were found in at least two families in this group.
The most frequent mutation was 5382insC (18 families), followed by C61G (7 families) and 4153delA (4 families).
2. Among 200 families representative for Poland with strong aggregation of breast/ovarian cancer, mutation of the
BRCA1 gene were found in 122 families (61%) and of the BRCA2 gene in seven families (3,5%). 119 out of 122
mutations of the BRCA1 gene (97,5%) were repeatable. Three recurrent mutations of the BRCA1 gene (5382insC,
C61G, 4153delA) characteristic for the Polish population were disclosed in 111 families representing 86% of all
pathogenic sequences of this gene. 3. The risk of ovarian cancer in carriers of the three most frequent recurrent
mutation of the BRCA1 gene in Poland is similar (OR 43.6 for 5382insC and 50 for 4153delA). The risk of breast
cancer is significantly different for 4153delA (OR 1) and for other mutations (OR 10.9). 4. Among 2012 unselected
breast cancers diagnosed in hospitals of nine Polish cities, mutations of the BRCA1 gene (5382insC, C61G, 4153delA)
were disclosed in 2.9% patients. CHEK2 alternation (1100delC, IVS2+1G>A, I157T) was discovered in 8.1% and
NBS1 mutation (657del5) in 0.8% of the patients. The changes were more frequent in the study than the control group.
However, the risk of breast cancer was significantly higher for only three of them. Two changes, namely 5382insC and
C61G of the BRCA1 gene revealed a high penetrance (OR 6.2 and 15.0, respectively), while I157T of the CHEK2
gene was associated with a low risk of breast cancer (OR 1.4). Mutations of the BRCA1, CHEK2 and NSB1 genes
were significantly more frequent in patients with breast cancer diagnosed prior to 50 years of age. The mean age at
diagnosis was 47.2 years for carriers of the BRCA1 mutation, 50.7 years for NBS1 and 54.2 for CHEK2. The mean
age at diagnosis in the group of patients without any if the mutations described above was 56.1 years. When breast
cancer patients with the diagnosis before and after 50 years of age were compared, the greatest difference in the
frequency of mutation was revealed for the BRCA1 gene (5.5% vs 1.5%).
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Introduction
BRCA1 and BRCA2 gene mutations have been
described as the most common cause of high hereditary
predisposition to breast and ovarian cancer. A major
objective is to define the type and frequency of these
mutations to obtain the most common changes. 
A genetics test, effective both medically and
economically, can be developed provided an
unlimited number of mutation analyses among
persons matching appropriate clinical and pedigree
data are performed.    
A large register of mutation carriers can be
organized only if unlimited access to DNA testing
can be achieved. In such a way actual data on
genotype-phenotype correlations can be obtained,
which would allow improvement in routine medical
practice, such as risk assessment depending on
BRCA1 gene mutation type. 
Among genes associated with increased genetic
predisposition to tumours the frequency of alterations
recognized until recently as polymorphism leading to
protein change is increased. Probably a proportion of
such alterations can be pathogenic and can
predispose to breast cancer similarly as with mutations. 
Study objectives
This study was undertaken to determine:
1. Type and prevalence of founder mutation BRCA1
and BRCA2 genes in Polish families with strong
aggregation of breast and/or ovarian cancer;
2. Risk of breast and/or ovarian cancer depending on
type of BRCA1 gene mutation;
3. Prevalence of BRCA1 mutation and of other alleles
presumably linked to predisposition to breast cancer
in unselected Polish patients with breast cancer. 
4. Increased risk of breast cancer in patients with
5972C/T polymorphism that alters the BRCA2
protein structure.
Materials, methods and results
Type and prevalence of BRCA1 and BRCA2 founder
mutations in Polish families with strong aggregation of
breast and/or ovarian cancer
Evidence for a strong domination effect by the
BRCA1 gene based on a limited number of recurrent
mutations in the Polish population
(Based on publication no. 1: Górski B et al.
Founder mutations in the BRCA1 gene in Polish families
with breast-ovarian cancer. Am J Hum Genet 2000;
66: 1963-1968)
Many different BRCA1 and BRCA2 mutations have
been described as a cause of high hereditary
predisposition to breast and ovarian cancer. I and
BRCA2 are both large genes, and complete analysis
of the coding regions is expensive and time-consuming.
Founder mutations of BRCA1 and BRCA2 gene in other
populations have also been described.
The presence of recurrent mutations in BRCA1 and
BRCA2 suggests the presence of founder effects; this
was first confirmed in the Ashkenazi Jewish population. 
BRCA1 mutations were significantly more frequent I familial aggregates of the tumor (10.8%), but were also
present in sporadic cases (1.8%). For the CHEK2 and NBS1 genes, there was no correlation between frequency
and family history of cancer in probands. 5. A higher frequency of heterozygous carriers of 5972C/T
polymorphism of the BRCA2 gene was demonstrated for breast cancer prior to 50 years of age (OR 1.4). the
risk of breast cancer prior to 50 years of age was particularly high in 5972T/T homozygote (OR 4.7). This
polymorphism was associated with breast cancer notable for intraductal growth.
Conclusions: 1. Efficient molecular diagnostics of genetic predisposition to breast/ovarian cancer in Poland
could be based on relatively simple tests disclosing some of the most frequent recurrent mutations of the BRCA1
gene. 2. The risk of breast cancer seems to be only slightly higher in carriers of some BRCA1 gene mutations.
This finding should be taken into account during work on prevention schemes for carriers of the BRCA1 mutations.
3. 5382insC and C61G mutations of the BRCA1 gene are linked with high risk of breast cancer. Changes in
the CHEK2 and NBS1 genes appear to be linked with a higher risk of breast cancers, particularly at young age.
However, penetrance in this case is low. All patients with breast cancer should be tested for BRCA1 gene mutations
because the percentage of mutations is also high in patients older than 50 years of age or without familiar
aggregation of breast/ovarian cancer. 4. Polymorphic changes in the BRCA2 gene sequence previously regarded
as non-pathogenic may nevertheless predispose, homozygotes in particular, to breast cancer. Apparently, the
recessive character of these changes is responsible for the negative family history in most cases. The use of DNA
tests is the only way to disclose increased risk of breast cancer in carriers of the 5972T/T mutation.
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In the studies concerning identyfing aforementioned
genes mutations it was not able to separate the diversity
of alterations which would allow creating diagnostic
tests consisting in examining limited numbers of DNA
changes. It was a consequence of the facts that the
groups of cases examined in early papers were not large
enough and the majority included sporadic or familiar
tumours, but without strong aggregation of breast and
ovarian cancers. The possibility of occurence of BRCA1
and BRCA2 gene mutations showing founder effects in
the Polish population was an open question. 
The present study suggests that in Poland families
with BRCA1 and BRCA2 have a genetic predisposition
to breast and ovarian cancers. 
Materials and methods
The study group consisted of 66 Polish families with
high hereditary predisposition to breast and ovarian
cancer who were drawn from the Oncology Centres in
Szczecin (58 families), Wroc³aw (7 families) and £ódŸ
(3 families), Poland.
In each family, at least three related female relatives
were affected by breast or ovarian cancer, and at least
one cancer was diagnosed at patient age <50 years.
A total of 27 families had both breast and ovarian
cancers, whereas 4 families had ovarian cancers only
and 35 families had breast cancer only. Blood samples
for genetic analyses of genes BRCA1 and BRCA2 were
taken from the youngest of these women. Genomic
DNA was prepared from peripheral blood leukocytes. 
The entire coding region of BRCA1 and BRCA2 was
screened for the presence of germline mutations in
BRCA1 and BRCA2, by use of SSCP followed by direct
sequencing of variants. Samples were sequenced with
the use of fluorescently labelled dideoxy-chain
terminators from the ABI Prism Kit (PE Biosystems), in a
model 373 automated DNA Sequencer (PE Biosystems).
Results
Mutations were found in 35 of families studied. All
but one of the mutations was detected within the
BRCA1 gene. The single family with a BRCA2 mutation
presented with the breast-ovarian cancer syndrome.
The mutation-detection rate was dependent on the
number of ovarian cancers: BRCA1 abnormalities were
identified in 100% of four families with ovarian cancers
only, in 67% of families with breast and ovarian cancers,
and in 34% of families with breast cancers only.
Seven distinct mutations were identified, and five of
these occurred in at least two different families. Three
BRCA1 mutations – 5382insC, C61G, and 4153delA
– accounted for 82% of all identified mutations. The
most frequent mutation in the present series was BRCA1
5382insC, which occurred in 18 families with
mutations. The second most commonly observed
mutation in the present study was BRCA1 C61G, which
occurred in 7 families with mutation. The third recurrent
mutation found in Polish patients, BRCA1 4153delA,
was detected in 4 families. 
Detailed description of BRCA1 and BRCA2 gene
mutation in a representative group of Polish families with
strong aggregation of breast or breast and ovarian cancer 
(Based on publication no. 2: Górski B et al. A high
proportion of founder BRCA1 mutations in Polish breast
cancer families. Int J Cancer 2004; 110: 638-686)
Three mutations in BRCA1 (5382insC, C61G and
4153delA) are common in Poland and account for the
majority of mutations identified to date in Polish breast
and breast-ovarian cancer families. To establish the
relative contributions of founder and nonfounder BRCA
mutations, we established the entire spectrum of BRCA1
and BRCA2 mutations in a large set of breast-ovarian
cancer families with origins in all regions of Poland. It
is not known, however, to what extent these three
founder mutations account for all of the BRCA
mutations distributed throughout the country.
Our goal was to describe the frequency of BRCA1
and BRCA2 constitutional mutations in a series of 200
breast cancer and breast-ovarian cancer families
representing all regions of Poland and to determine
the relative contributions of founder and nonfounder
mutations. Our study was conducted to advise on
national genetic screening policies for the Polish
population.
Materials and methods
A total of 200 families were selected for study. One
hundred families contained three or more cases of breast
cancer and no case of ovarian cancer, and 100 families
contained at least one case of breast cancer and one
case of ovarian cancer (minimum 3 cases total). These
families were selected for study from among those
seeking genetic counselling at one of 18 affiliated cancer
genetics centres situated throughout Poland. Information
about cancers in relatives was obtained from patient
interview. Families were recruited from the 18 centres so
that the number of families contributed by each centre
corresponded to the size of the reference population.
Genomic DNA was prepared from peripheral blood
leukocytes using a nonenzymatic, rapid method.
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Table 1. Mutation of BRCA1 and BRCA2 genes in 66 families with evidence of strong genetic predisposition to breast and/or ovarian cancer
Family No. Exon Codon Mutation Family history of cancer
breast cancer ovarian cancer other
BRCA1
4506 20 1756 5382insC 3
3311 20 1756 5382insC 3
4412 20 1756 5382insC 3
1633 20 1756 5382insC 3 colon
4508 20 1756 5382insC 2 1
3319 20 1756 5382insC 2 1
3088 20 1756 5382insC 2 2 lymphoma
3572 20 1756 5382insC 3
4545 20 1756 5382insC 3 colon, stomach
1738 20 1756 5382insC 4 3 colon
1582 20 1756 5382insC 3 prostate
4478 20 1756 5382insC 3
1387 20 1756 5382insC 4 1 colon
2863 20 1756 5382insC 4 2
4968 20 1756 5382insC 4 stomach, CSU, unknown
5715 20 1756 5382insC 3
5726 20 1756 5382insC 1 2
4030 20 1756 5382insC 3 lung, leukaemia
1581 5 61 C61G 2 2 CSU, unknown
1888 5 61 C61G 4
4859 5 61 C61G 3
3004 5 61 C61G 7
4858 5 61 C61G 4
5850 5 61 C61G 2 1
4854 5 61 C61G 3 skin
2984 11 1345 4153delA 2 1
4278 11 1345 4153delA 4
3080 11 1345 4153delA 2 2 colon
5939 11 1345 4153delA 4 leukaemia
1601 2 23 185delAG 3
703 2 23 185delAG 3 lung
3910 11 1234 3819del5 3
5763 11 1234 3819del5 2 2 colon, lung
5746 5 64 C64G 4 1 lung, colon, leukaemia
BRCA2
3874 27 3401 T3401M 2 1 colon
CSU – cancer site unknown
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For each family, a single affected woman was
selected for study. In general, this was the youngest
affected woman in the family. When more than one
blood sample was available for testing, the sample
from the youngest woman was chosen.
The entire coding sequence of the BRCA1 and
BRCA2 genes, including splice sites, was amplified by
PCR, with minor modifications. Exon 11 of the BRCA1
gene and exons 10 and 11 of BRCA2 were amplified,
each in one fragment, using primers located in the
adjacent introns and the Expand Long Template PCR
Kit. Purified PCR products were sequenced directly
using the DNA Sequencing Kit with BigDye Terminator,
version 3.0 (Applied Biosystems). Products of
sequencing reactions were separated and analyzed
on a 377 DNA Sequencer (Applied Biosystems).
Results
A BRCA1 mutation was detected in 122 families
(61%) and a BRCA2 mutation in 7 (3.5%) families –
Tables 2 and 3. Of the 122 BRCA1 mutations, 119
(97.5%) were found in more than one family. The 3 most
common mutations accounted for 111 of the 122
(91.0%) BRCA1 mutations detected and for 86.0% of
all detected mutations. There was no clear difference in
the distribution of individual mutations between families
with and without ovarian cancer, with the possible
exception of the 4153delA mutation. Of the 12 families
with this specific mutation, 9 had one or more cases of
ovarian cancer. There were no clear differences in the
prevalence of mutations by geographic region. In all,
BRCA2 mutations were unique (i.e. none seen in more
than one family). Six of the 7 BRCA2 mutations were
found in families with site-specific breast cancer, and
one was found in a breast-ovarian cancer family.
During sequencing several polymorphic changes
within BRCA1 and BRCA2 were identified. Also, BRCA1
gene polymorphisms localized within promoter exons
11, 13 and 16 and introns 9 and 18 showed complete
linkage. Because there was no exception to the above
observation among heterozygote carriers of the above
polymorphism it is possible to exclude large deletions
of the BRCA1 gene covering polymorphic regions of
these genes in more than one third (38%) of
examined families without mutations detectable by
sequencing (Table 4).  We found 5 DNA alterations
which were not clarified as neutral polymorphism or
changes associated with predisposition to cancer of
the breast or ovary (Table 3).
Table 2. Frequency of BRCA1 mutations in 200 families with evidence
of strong genetic predisposition to breast and ovarian cancer
Mutation Exon Families Families Total
with organ-specific with breast
breast cancer and ovarian 
cancer
5382insC 20 36 32 68 (34.0%)
C61G 5 16 15 31 (15.5%)
4152delA 11 3 9 12 (6.0%)
5370C/T 20 3 – 3 (1.5%)
3819del5 11 1 2 3 (1.5%)
794delT 11 – 2 2 (1.0%)
185delAG 2 – 1 1 (0.5%)
2985del5 11 – 1 1 (0.5%)
5149del4 17 1 – 1 (0.5%)
total 60 (60%) 62 (62%) 122 (61.0%)
Table 3. Frequency of mutations and of unclassified variants of the
BRCA2 gene in 200 families with evidence of strong genetic
predisposition to breast or breast and ovarian cancer
Mutation Exon Families Families Total
with organ-specific with breast
breast cancer and ovarian 
cancer
488delCT 3 – 1 1
3427delA 11 1 – 1
5467insT 11 1 – 1
7235G/A 13 1 – 1
8138del5 17 1 – 1
9068delA 22 1 – 1
9630delC 25 1 – 1
Total 6 (6%) 1 (1%)7 (3.5%)
Sequence Exon Families Families Total
variants with organ-specific with breast
breast cancer and ovarian 
cancer
1093A/C 10 1 2 3
2578A/G 11 – 1 1
4486G/T 11 1 2 3
5972C/T 11 2 1 3
9079G/A 22 1 – 1
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Assessment of the risk of breast/ovarian cancer
depending on type of BRCA1 gene mutation –
evidence for low breast cancer risk in carriers of the
4153delA mutation
(Based on publication No. 3: Górski B et al. A
protein truncating BRCA1 allele with a low penetrance
of breast cancer. J Med Genet 2004; 41: 130-131)
Recurrent BRCA1 gene mutation can be detected
in families with hereditary site specific predisposition
to breast cancer as well as in families with breast and
ovarian cancer.
There is some evidence that families with mutations
in the central part of BRCA1 have a higher than
expected ratio of ovarian to breast cancers, due to a
lower than average risk of breast cancer. The absolute
and relative risks of breast and ovarian cancers
associated with different mutations have been difficult
to quantify, in part because of the large number of
different mutations in the gene, the rarity of mutations
in the general population, and the expense of testing.
Poland is ideally suited to the study of the genetic
epidemiology of BRCA1 mutations because three
common BRCA1 mutations comprise 91% of all BRCA1
mutations found in the population.
Materials and methods
To estimate the prevalences and relative risks
associated with each of the three founder mutations,
we genotyped 2012 unselected cases of breast cancer,
460 unselected cases of ovarian cancer, and 2000
population controls. The control population consisted
of 1000 newborn children from throughout Poland
and 1000 adults unaffected with cancer from the
practices of family physicians in Szczecin. Patients were
unselected for age or for family history, and had been
diagnosed between 1999 and 2004. Genomic DNA
was prepared from peripheral blood leukocytes from
patients with breast and ovarian cancer and from adult
patients from the control group. In the group of
newborn children genomic DNA was prepared from
umbilical cord blood leukocytes.
Analysis for three common Polish mutations
(4153delA, C61G and 5328insC) was carried out by
multiplex PCR. The third mutation (C61G) generates
a novel restriction enzyme site in exon 5. This mutation
is detected after digesting amplified DNA with AvII.
Research in the breast and ovarian cancer group
and in the control group describes the frequency of
particular mutations of the BRCA1 gene. We also
compared the ratio of breast to ovarian cancers in an
independent set of families with different kinds of
BRCA1 mutation.
Results
On the basis of frequency of particular BRCA1 gene
mutations in the unselected groups with breast and
ovarian cancer compared with the control group the
risk levels of cancer development were specified. 
The equivalent odds ratios for ovarian cancer for
the 5382insC mutation are 43.6 and for the 4153delA
mutation 50.0. Among carriers of the 4153delA
mutation, the odds ratio for breast cancer is 1.0.
Table 4. BRCA1 gene polymorphism in probands without BRCA1 and
BRCA2 gene mutation as shown by sequencing
Nucleotide Amino acid swap Exon/intron Frequency
IVS8-58delT NC 7 Wt/Wt 33 
WT/delT 30 
delT/delT 8
1186A/G Gln356Arg 11 6
2430T/C Leu771Leu 11 T/T 33
T/C 30
C/C 8
2731 C/T Pro871Leu 11 C/C 33      
C/T 30      
T/T 8
3367A/G Lys1183Arg 11 A/A 33       
A/G 30     
G/G 8
4427T/C Ser1436Ser 13 T/T 33
T/C 30       
C/C 8
4956A/G Ser1613Gly 16 A/A 33       
A/G 30     
G/G 8
IVS18+66G/A NC 18 G/G 33       
G/A 30       
A/A 8
IVS20+60ins12 NC 20 2
NC – non-coding sequence; Wt – wild-type sequence
Table 5. Prevalence of BRCA1 gene mutations in unselected breast
and ovarian cancer groups and in controls
Parameters C61G 4153delA 5382insC Total
breast cancer 15 (0.7%) 1 (0.05%) 43 (2.1%) 59 (2.9%)
ovarian cancer 13 (3.6%) 8 (2.2%) 28 (7.7%) 49 (13.5%)
control group 1 (0.05%) 1 (0.05%) 4 (0.2%) 6 (0.3%)
Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population
Hereditary Cancer in Clinical Practice 2006; 4(3)148
Among carriers of the 5382insC mutation, the odds
ratio for breast cancer is 10.9. To confirm the
hypothesis that the 4153delA BRCA1 mutation confers
a comparatively low risk of breast cancer, we compared
the ratio of breast to ovarian cancers in an independent
set of 460 families who had been referred to the
hereditary cancer clinic of Szczecin because of two or
more cases of breast or ovarian cancer.
These families contained a total of 979 cases of
breast cancer and 376 cases of ovarian cancer.
Among the 44 families with the 4153delA mutation,
there were 51 breast and 74 ovarian cancers. Among
the 416 families with one of the other two mutations
(C61G and 5872insC) there were 928 breast and 302
ovarian cancers. Breast cancer is clearly under-
represented in families with the 4153delA mutation. 
Prevalence of BRCA1 gene mutation and of other
alleles presumably linked to predisposition to breast
cancer in unselected Polish patients with breast cancer
(Based on publication No. 4: Górski B et al. Breast
cancer predisposing alleles in Poland. Breast Cancer
Res Treat 2005; 92: 19-24)
Mutant alleles of several genes in the DNA repair
pathway have been found to predispose women to
breast cancer. From a public health perspective, the
importance of a given allele in a population is
determined by the frequency of the allele and by the
relative risk of breast cancer that it confers.  
In Poland founder alleles of the CHEK2 and NBS1
genes have been associated with an increased risk of
breast cancer. 
The purpose of the present study is to estimate the
prevalence of seven deleterious alleles of three breast
cancer predisposing genes (BRCA1, CHEK2, NBS1) in
unselected breast cancers. 
Materials and methods
We screened 2012 unselected cases of breast
cancer. Each newly diagnosed woman with breast
cancer agreed to provide a blood sample for genetic
testing and provided information about her family
history of breast cancer.
Three control groups were combined. The first
group consisted of 2000 newborn children from ten
hospitals throughout Poland (Szczecin, Bia³ystok,
Gorzów, Katowice, Wroc³aw, Poznañ, Opole, £ódŸ and
Rzeszów). Samples of cord blood from unselected
infants were forwarded to the study centre in Szczecin.
The second control group was taken from adult patient
lists of three family doctors practicing in the Szczecin
region. 1000 controls were selected at random from
the patient lists of these family doctors. The third control
group, with 1000 patients, consisted of adults from
Szczecin who submitted blood for paternity testing. 
Analysis of BRCA1 mutations. Mutation analysis for
three common Polish mutations (4153delA, C61G and
5328insC) was carried out by a multiplex specific
polymerase chain reaction (PCR) assay. To evaluate the
accuracy of the multiplex technique the results of 30
samples, representing each of the three mutations and
normal DNA samples, were compared.  The results of
the multiplex PCR assay and the direct DNA sequencing
were 100% concordant.
Analysis of CHEK2 mutations. The IVS2+1G>A
and 430T>C mutations were identified by RFLP-PCR
using Hpy 188III (New England Biolabs). The reverse
primer introduced an artificial restriction site for PstI
enzyme. 
1100delC was analyzed using an allele-specific
oligonucleotide (ASO-PCR).
Analysis of 657del5 gene NBS1 mutations. Data
collection and analysis was performed using the ASO-
PCR technique.
In cases in which mutations in BRCA1, CHEK2, and
NBS1 genes were detected using the above-mentioned
methods, results were verified by sequencing.
Results
The prevalence, odds ratio and attributable risk
estimate associated with each mutant allele (BRCA1,
CHEK2 and NBS1) are presented in Table 6. The highest
odds ratio was associated with missense mutation I C61G
and 5382insC. The most common allele in control and
patient groups was CHEK2 IVS+1G>A mutation. The
presence of any CHEK2 mutation was associated with a
50% increased risk of cancer (odds ratio = 1.4).
Patients diagnosed under the age of 50 carried a
mutation more often. The mean ages of patients were
47.2 years for the BRCA1-positive cases, 50.7 years for
the NBS1-positive cases, 54.2 years for the CHEK2-
positive cases and 56.1 years for the cases with no
mutation detected. 
Among the CHEK2-positive cases the average age of
women with a IVS2+1G>A and 1100delC mutation
was 51.0 years, and for women with the Ile157Thr
mutation it was 55.6 years.
The greatest contrast with age group was for
BRCA1; the prevalence of BRCA1 mutations was 5.5%
among cases diagnosed 50 years and younger and
1.5% for those diagnosed after age 50.
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A BRCA1 mutation was much more common in
the familial versus non-familial cases (10.8% versus
1.3%) but this was not true for NBS1 (0.8% for both
groups) or for CHEK2 (8.8% for familial versus 7.9%
for non-familial).
Assessment of breast cancer risk in patients with
a polymorphism that alters BRCA2 protein structure
– detection of increased breast cancer risk in young
women with 5972C/T polymorphism of the BRCA2
gene
(Based on publication No. 4: Górski B et al. A
common missense variant in BRCA2 predisposes
to early breast cancer. Breast Cancer Res 2005; 7:
1023-1027) 
Mutations in the BRCA2 gene are one of the
two major causes of hereditary breast cancer. 
A few missense mutations in BRCA2 are
believed to have a similarly high penetrance,
apart from more common neutral polymorphisms.
It is often difficult to classify a particular sequence
variant as a mutation or a polymorphism. 
There are several approaches to identifying
low-penetrance candidate genes for breast
cancer. Several deleterious founder alleles have
been identified in BRCA1, but to date no founder
mutation in BRCA2 has been identified.  There
are a few common variant alleles in BRCA2 in
Poland; one of these (C5972T) changes the
amino acid sequence of BRCA2 from methionine
to hreonine at codon 915.
The study population included prospectively
ascertained cases of invasive breast cancer
diagnosed at 50 years of age or less and the
control group.
Materials and methods
We genotyped 3,241 cases of breast cancer
diagnosed at less than 51 years of age,
unselected for family history, from 18 hospitals
throughout Poland. The control group consisted
of 1993 newborn children and 798 adult patients
unselected for family history.
The C5972T variant was analyzed by restriction
fragment length polymorphism PCR-RFLP using
the forward primer introducing an artificial
restriction site for the Mph1103I enzyme.
Results
The C5972T variant was detected in 5.8% of
Polish controls. The overall effect was significant for
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Table 7. Prevalence of C5972T polymorphism in the group of unselected breast cancers diagnosed prior to 50 years of age and in the
control group
Parameters Control group Breast cancers Odds ratio p-value 95%CI
all cancer cases
CC 2630 3039 1.0
CT 159 191 1.0 0.74 0.8-1.3
TT 2 11 4.8 0.02 1.1-21.4
CT+TT 161 202 1.1 0.45 0.9-1.3
total 2791 3241
cancer diagnosed prior to 40 years of age
CC 2630 598 1.0
CT 159 51 1.4 0.04 1.0-2.0
TT 2 1 2.2 0.46 0.2-23.7
CT+TT 161 52 1.4 0.03 1.0-1.9
total 2791 650
cancer diagnosed past 41 years of age
CC 2630 2441 1.0
CT 159 140 0.9 0.68 0.8-1.2
TT 2 10 5.4 0.02 1.2-24.6
CT+TT 161 150 1.0 0.97 0.8-1.3
total 2791 2591
– Table 7. We reviewed the association between the
BRCA2 variant in different histological subgroups and
found the effect most pronounced in women who had
ductal carcinoma in situ (DCIS) with micro-invasion –
Table 8.
We found 13 5972C/T homozygotes – 2 in the
control group and 11 in the patient group with breast
cancer (OR 4.7). Existing reports on the C5972T
variant do not record any case of homozygote TT
genotypes. It is of interest that the heterozygote state
was associated with early onset breast cancer and the
homozygote state with later onset cancer.
Family history indicates the occurrence of one or
more breast or ovarian cancers among first- and
second-degree relatives. For age and tumour size
comparisons, p-values and confidence intervals refer
to the difference of means. Data were missing from
the following categories and these cases were excluded
from the specific calculations: histology – 909 cases;
multi-focality – 1774 cases; bilaterality – 744 cases;
oestrogen receptor status – 1746 cases; family history
– 756 cases; family history in group diagnosed <40
– 150 cases. Patients who received neo-adjuvant
chemotherapy were excluded from all analyses with
the exception of family history. 184 patients with BRCA1
mutations were excluded from all analyses. ER+,
oestrogen receptor expression positive.
Summary of results 
1. Among 66 families from several regions in Poland
with a strong aggregation of breast/ovarian cancer,
founder mutations of the BRCA1 gene were
disclosed in 34 families and of the BRCA2 gene in
one family. Altogether, seven different mutations
were disclosed. Five mutations were found in at least
two families in this group. The most frequent
mutation was 5382insC (18 families), followed by
C61G (7 families) and 4153delA (4 families).
2. Among 200 families representative for Poland with
strong aggregation of breast/ovarian cancer,
mutations of the BRCA1 gene were found in 122
families (61%) and of the BRCA2 gene in seven
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Table 8. Breast cancer cases associated with 5972C/T or TT variants in comparison to the wild 5972C/C sequence
Parameters 5972C/T or TT 5972C/C OR p-value 95%CI
n % n %
Histological diagnosis
ductal cancer (%) 41 36 604 35 1.04 0.83 0.7-1.5
lobular cancer (%) 22 19 364 21 0.90 0.70 0.5-1.5
DCIS + microinvasion 22 19 121 7 3.18 <0.0001 1.9-5.2
medullar cancer (%) 7 6 122 7 0.86 0.71 0.4-1.9
tubular or tubulolobular cancer (%) 3 3 104 6 0.42 0.13 0.1-1.3
other 19 17 416 24 0.63 0.09 0.4-1.0
multifocal cancer (%) 19 30 211 23 1.47 0.17 0.8-2.6
bilateral cancer (%) 7 5 63 3 1.71 0.18 0.7-3.8
ER + (%) 50 67 583 62 1.24 0.40 0.7-2.0
Positive family history
all cases 32 21 569 26 0.72 0.14 0.5-1.2
cases diagnosed <40 years of age 4 10 97 24 0.36 0.06 0.1-1.1
X X ΔX p-value 95%CI
mean age at diagnosis (years) 43.9 44.4 0.5 0.34 -2
mean tumour size (cm) 2.0 2.1 0.1 0.41 -0.4
families (3.5%). 119 out of 122 mutations of the
BRCA1 gene (97.5%) were repeatable. Three
recurrent mutations of the BRCA1 gene (5382insC,
C61G, 4153delA) characteristic for the Polish
population were disclosed in 111 families representing
86% of all pathogenic sequences of this gene. 
3. The risk of ovarian cancer in carriers of the three most
frequent recurrent mutations of the BRCA1 gene in
Poland is similar (OR 43.6 for 5382insC and 50 for
4153delA). The risk of breast cancer is significantly
different for 4153delA (OR 1) and for other mutations
(OR 10.9).
4. Among 2012 unselected breast cancers diagnosed in
hospitals of nine Polish cities, mutations of the BRCA1
gene (5382insC, C61G, 4153delA) were disclosed
in 2.9% of patients. CHEK2 alternation (1100delC,
IVS2+1G>A, I157T) was discovered in 8.1% and
NBS1 mutation (657del5) in 0.8% of patients. The
changes were more frequent in the study than the
control group. However, the risk of breast cancer was
significantly higher for only three of them. Two changes,
namely 5382insC and C61G of the BRCA1 gene,
revealed a high penetrance (OR 6.2 and 15.0,
respectively), while I157T of the CHEK2 gene was
associated with a low risk of breast cancer (OR 1.4).
Mutations of the BRCA1, CHEK2 and NSB1 genes
were significantly more frequent in patients with breast
cancer diagnosed prior to 50 years of age. The mean
age at diagnosis was 47.2 years for carriers of the
BRCA1 mutation, 50.7 years for NBS1 and 54.2 for
CHEK2. The mean age at diagnosis in the group of
patients without any of the mutations described above
was 56.1 years.
When breast cancer patients diagnosed before and
after 50 years of age were compared, the greatest
difference in the frequency of mutations was revealed
for the BRCA1 gene (5.5% vs. 1.5%).
BRCA1 mutations were significantly more frequent I
familial aggregates of the tumour (10.8%), but were
also present in sporadic cases (1.8%). For the CHEK2
and NBS1 genes, there was no correlation between
frequency and family history of cancer in probands.
5. A higher frequency of heterozygous carriers of 5972C/T
polymorphism of the BRCA2 gene was demonstrated
for breast cancer prior to 50 years of age (OR 1.4).
The risk of breast cancer prior to 50 years of age was
particularly high in 5972T/T homozygotes (OR 4.7).
This polymorphism was associated with breast cancer
notable for intraductal growth.
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Conclusions
1. Efficient molecular diagnostics of genetic predisposition
to breast/ovarian cancer in Poland could be based on
relatively simple tests disclosing some of the most
frequent recurrent mutations of the BRCA1 gene.
2. The risk of breast cancer seems to be only slightly
higher in carriers of some BRCA1 gene mutations. This
finding should be taken into account during work on
prevention schemes for carriers of BRCA1 mutations.
3. 5382insC and C61G mutations of the BRCA1 gene
are linked to high risk of breast cancer. Changes in
the CHEK2 and NBS1 genes appear to be linked to
a higher risk of breast cancers, particularly at young
age. However, penetrance in this case is low. All
patients with breast cancer should be tested for BRCA1
gene mutations because the percentage of mutations
is also high in patients older than 50 years of age or
without familiar aggregation of breast/ovarian cancer.
4. Polymorphic changes in the BRCA2 gene sequence
previously regarded as non-pathogenic may
nevertheless predispose, homozygotes in particular,
to breast cancer. Apparently, the recessive character
of these changes is responsible for the negative
family history in most cases. The use of DNA tests
is the only way to disclose increased risk of breast
cancer in carriers of the 5972T/T mutation.
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